Significant milestones reached, well capitalised and positioned for future growth
hVIVO PLC (AIM:HVO) World Vaccine Congress Presentation
hVIVO plc (AIM & Euronext: HVO) , (formerly Open Orphan plc) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using
Abingdon Health PLC (AIM:ABDX) Senzo and Abingdon Health enter into strategic partnership
Abingdon Health’s CDMO service to support Senzo in leveraging its innovative, high-accuracy Amplified Lateral Flow (ALF) point-of-care diagnostics platform technology across multiple product opportunities
Genedrive PLC (AIM:GDR) Commence of roll out in Greater Manchester
Genedrive ® MT-RNR1 to commence roll out in Greater Manchester Project to follow NICE final recomendations scheduled for end of this month
Breaking: The UK Government confirms new pay offer for NHS staff in England
The deal comprises three components, namely a pay rise of approximately 5%, along with two separate one-time payments – a 2% bonus and a 4% Covid payment.
OKYO Pharma LTD has commenced the trial process for its treatment of dry eye disease.
OKYO Pharma Ltd (LSE: OKYO, NASDAQ: OKYO) announced that the ClinicalTrials.gov public website (ClinicalTrials.gov Identifier: NCT05759208) now includes information about its trial that assesses the safety and effectiveness of OK-101
hVIVO PLC (AIM:HVO) Omicron human challenge model update
hVIVO plc (AIM & Euronext: HVO), (formerly Open Orphan plc) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human
Poolbeg Pharma PLC (AIM:POLB) POLB 001 patent portfolio strengthened
POLB 001 patent portfolio strengthened through granting of US patent
Abingdon Health PLC (AIM:ABDX) AppDx ® lateral flow smartphone reader granted further patent
York, U.K. 7 March 2023: Abingdon Health plc (AIM: ABDX), a leading international lateral flow contract development and manufacturing organisation (CDMO), announces the granting of an additional patent for its
Q1 2023 overview: top 10 high-risk holdings
FTSE small-cap stocks remain my favoured high-risk investments. Here are 10 to consider for 2023.
Poolbeg Pharma Plc (AIM:POLB) Positive Results from POLB 001 LPS Human Challenge Trial
Strong potential for POLB 001 to be a blockbuster treatment for severe influenza